Clinical trial THR-317-002: Efficacy and safety of THR-317 with ranibizumab in the treatment of diabetic macular oedema
Clinical Trial KESTREL: Efficacy and safety of brolucizumab in comparison with aflibercept in diabetic macular edema
Clinical Trial OAKS and DERBY: Efficacy and safety of APL-2 in the treatment of geographic atrophy secondary to AMD
Clinical trial OPH2005: Efficacy and safety of Zimura in the treatment of Stargardt’s disease
Geographic atrophy phenotype identification by cluster analysis
Drusen Ooze: A Novel Hypothesis in Geographic Atrophy
A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate
Feeder vessel laser photocoagulation for idiopathic, subfoveal polypoidal choroidal vasculopaty not responding to eithelial growth factor therapy or photodynamic therapy
Direct Visualization of a New Choroidal Vessel on Spectral-Domain Optical Coherence Tomography
Proxima A: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29633)
Proxima B: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29639)
Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
Correspondence. Wedge-Shaped Subretinal hyporeflectivity in GA.
Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
Scheduled versus Pro Re Nata Dosing in the VIEW Trials.